Cargando…

Targeting the FGF/FGFR axis and its co-alteration allies

BACKGROUND: We analyzed the FGF/FGFR and co-alteration cancer landscape, hypothesizing that combination therapy might be useful in the presence of co-drivers. MATERIALS AND METHODS: We describe FGF/FGFR-altered pathways, prognosis, and co-alterations [cBioPortal (N = 7574)] and therapeutic outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uehara, Y., Ikeda, S., Kim, K.H., Lim, H.J., Adashek, J.J., Persha, H.E., Okamura, R., Lee, S., Sicklick, J.K., Kato, S., Kurzrock, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808461/ https://www.ncbi.nlm.nih.gov/pubmed/36455506 http://dx.doi.org/10.1016/j.esmoop.2022.100647

Ejemplares similares

Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response
por: Persha, Hanna E., et al.
Publicado: (2022)

Targeting G(1)/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens
por: Kato, Shumei, et al.
Publicado: (2021)

Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis
por: Zhang, Jinglin, et al.
Publicado: (2019)

Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
por: Shaya, Justin, et al.
Publicado: (2023)

Enterohepatic bacterial infections dysregulate the FGF15-FGFR4 endocrine axis
por: Romain, Guillaume, et al.
Publicado: (2013)

Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
por: Yang, Chaofeng, et al.
Publicado: (2012)

Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials
por: Szeto, C.W., et al.
Publicado: (2022)

Addiction of mesenchymal phenotypes on the FGF/FGFR axis in oral squamous cell carcinoma cells
por: Osada, Asami Hotta, et al.
Publicado: (2019)

FGF/FGFR signaling in health and disease
por: Xie, Yangli, et al.
Publicado: (2020)

FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer
por: Nomura, S, et al.
Publicado: (2008)

A Network Map of FGF-1/FGFR Signaling System
por: Raju, Rajesh, et al.
Publicado: (2014)

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
por: Okamura, Ryosuke, et al.
Publicado: (2020)

Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas
por: Jomrich, Gerd, et al.
Publicado: (2019)

LHX2 facilitates the progression of nasopharyngeal carcinoma via activation of the FGF1/FGFR axis
por: Xie, Tao, et al.
Publicado: (2022)

Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies
por: Gupta, Diviya, et al.
Publicado: (2022)

Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors
por: Jardim, Denis L F, et al.
Publicado: (2022)

Identification of a peptide antagonist of the FGF1–FGFR1 signaling axis by phage display selection
por: Lipok, Magdalena, et al.
Publicado: (2019)

FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
por: Raja, Aroosha, et al.
Publicado: (2019)

Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity
por: Agrawal, Archita, et al.
Publicado: (2018)

Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary
por: Kato, Shumei, et al.
Publicado: (2021)

Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers
por: Okamura, Ryosuke, et al.
Publicado: (2020)

FGF19/FGFR4 signaling axis confines and switches the role of melatonin in head and neck cancer metastasis
por: Lang, Liwei, et al.
Publicado: (2021)

FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
por: Grabner, Alexander, et al.
Publicado: (2017)

The paradox of cancer genes in non-malignant conditions: implications for precision medicine
por: Adashek, Jacob J., et al.
Publicado: (2020)

Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies
por: Shayeb, Akram Mesleh, et al.
Publicado: (2023)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

Osteocyte-Specific Deletion of Fgfr1 Suppresses FGF23
por: Xiao, Zhousheng, et al.
Publicado: (2014)

The Emerging Role of the FGF/FGFR Pathway in Gastrointestinal Stromal Tumor
por: Astolfi, Annalisa, et al.
Publicado: (2020)

FGF/FGFR Pathways in Multiple Sclerosis and in Its Disease Models
por: Rajendran, Ranjithkumar, et al.
Publicado: (2021)

Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
por: Liu, Guihong, et al.
Publicado: (2021)

Roles of the FGF-FGFR Signaling System in Cancer Development and Inflammation
por: Wiedlocha, Antoni, et al.
Publicado: (2021)

Differential Fibroblast Growth Factor 8 (FGF8)-Mediated Autoregulation of Its Cognate Receptors, Fgfr1 and Fgfr3, in Neuronal Cell Lines
por: Mott, Natasha N., et al.
Publicado: (2010)

Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer
por: Adashek, Jacob J., et al.
Publicado: (2020)

High prevalence of clonal hematopoiesis‐type genomic abnormalities in cell‐free DNA in invasive gliomas after treatment
por: Okamura, Ryosuke, et al.
Publicado: (2021)

FGFR2 Mutation p.Cys342Arg Enhances Mitochondrial Metabolism-Mediated Osteogenesis via FGF/FGFR-AMPK-Erk1/2 Axis in Crouzon Syndrome
por: Wang, Yidi, et al.
Publicado: (2022)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230
por: Blackwell, Christina, et al.
Publicado: (2016)

Expression Atlas of FGF and FGFR Genes in Pancancer Uncovered Predictive Biomarkers for Clinical Trials of Selective FGFR Inhibitors
por: Li, Yuan, et al.
Publicado: (2020)

Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia
por: Wu, Ai-Luen, et al.
Publicado: (2013)

Binding Pattern Reconstructions of FGF-FGFR Budding-Inducing Signaling in Reef-Building Corals
por: Guo, Zhuojun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fnp8ia48sgi5g222qh8kr9mukr